Industry Forecast: Ischemic Heart Disease (IHD) Drugs Market to Generate $7.7 Billion Revenue by 2029
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Much Is the Global Ischemic Heart Disease (IHD) Drugs Market Valued at Present and by 2029?
The market for drugs treating ischemic heart disease (IHD) has been demonstrating consistent growth over the past few years. The size of the market is projected to rise from $6.36 billion in 2024 to $6.65 billion in 2025, maintaining a compound annual growth rate (CAGR) of 4.5%. Several factors such as the increasing global incidence of ischemic heart disease, enhanced awareness and diagnostic methods, modifications in lifestyle and diet, governmental actions promoting cardiovascular health, partnerships for clinical trial testing, and insurance and reimbursement policies have played significant roles in the historical growth of this market.
In the next few years, the ischemic heart disease (IHD) drugs market is projected to experience consistent growth, reaching “$7.7 billion by 2029, with a compound annual growth rate (CAGR) of 3.7%“. This growth during the forecast period is linked to factors like the ageing population, personalized medicine methodologies, preventative cardiovascular measures, worldwide healthcare policies and initiatives, and international research partnerships. The period is also expected to witness trends such as a shift towards precision medicine methods, the introduction of innovative anti-atherogenic agents, advancements in lipid-lowering treatment, the inclusion of anti-inflammatory agents, and the creation of antithrombotic and antiplatelet drugs.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13467&type=smp
#What Drivers Are Influencing Growth In The Ischemic Heart Disease (IHD) Drugs Market?
The surge in obesity and diabetes rates is predicted to stimulate the ischemic heart disease (IHD) drugs market’s expansion. Metabolic diseases such as diabetes, characterized by elevated blood sugar over a prolonged period, and obesity, defined by excessive body fat accumulation that impairs health, result in higher demand for ischemic heart disease drugs. These drugs help manage cardiovascular risk factors like hypertension and dyslipidemia, thus decreasing the probability of ischemic heart disease. The World Obesity Federation, a UK organization dedicated to combating obesity worldwide, projected in 2022 that by 2030, one billion people, including 1 in 5 women and 1 in 7 men, will be obese. Furthermore, according to the National Health Service, another UK government body, the NHS in 2023 identified an extra 549,000 individuals in England at risk of type 2 diabetes. Hence, the total number of people with non-diabetic hyperglycemia, also known as pre-diabetes, registered with a GP soared to 3,615,330 which is near about 20% rise compared to 3,065,825 in 2022. Therefore, the escalating prevalence of obesity and diabetes propels the growth of the ischemic heart disease (IHD) drugs market.
The ischemic heart disease (ihd) drugs market covered in this report is segmented –
1) By Drug Class: Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents
2) By Disease Class: Angina Pectoris, Myocardial Infarction
3) By End User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Anti-Dyslipidemic Drugs: Statins, Fibrates, Niacin, Cholesterol Absorption Inhibitors
2) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines
3) By Beta-Blockers: Cardioselective Beta-Blockers, Non-Selective Beta-Blockers, Vasodilating Beta-Blockers
4) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril, Lisinopril, Ramipril
5) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan
6) By Vasodilators: Nitroglycerin, Isosorbide Dinitrate, Hydralazine
7) By Antithrombotic Agents: Antiplatelet Drugs, Anticoagulants
What Trends Are Currently Influencing Growth In The Ischemic Heart Disease (IHD) Drugs Market?
Leading organizations in the Ischemic Heart Disease (IHD) drugs market are upping their game by focusing on the development of innovative myosin inhibitors to establish competitive dominance in the industry. These inhibitors are drugs designed to diminish myosin activity in cardiac muscles, thereby lessening force of contraction. They come particularly handy for conditions such as Hypertrophic Cardiomyopathy (HCM) where extreme muscle thickening compromises the functioning of the heart. For instance, in April 2022, US-based pharmaceutical major Bristol Myers Squibb introduced Camzyos (mavacamten), the inaugural cardiac myosin inhibitor given the nod for treatment of adult patients showing symptoms of New York Heart Association class II-III obstructive hypertrophic cardiomyopathy (HCM). This new drug aims to enhance functional capacity and symptoms, functioning as an allosteric and reversible inhibitor tailored for cardiac myosin. This reduces hypercontractility and left ventricular hypertrophy, and amplifies cardiac filling pressures, thereby aiding in the reduction of dynamic left ventricular outflow tract (LVOT) obstruction.
Which Companies Play A Key Role In The Development Of The Ischemic Heart Disease (IHD) Drugs Market?
Major companies operating in the ischemic heart disease (ihd) drugs market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sandoz Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Lupin Limited, Recordati S.p.A., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alembic Pharmaceuticals Ltd., Eagle Pharmaceuticals Inc., Accord Healthcare Limited, Macleods Pharmaceuticals Ltd., WG Critical Care LLC, Novitium Pharma LLC
What Are The Key Regional Developments Shaping The Ischemic Heart Disease (IHD) Drugs Market?
North America was the largest region in the ischemic heart disease (IHD) drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ischemic heart disease (ihd) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=13467&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
